Exciting news for the Kennedy’s Disease community! At the 2025 World Muscle Society International Congress in Vienna, AnnJi Pharmaceutical Co., Ltd. presented groundbreaking Phase 2a results for AJ201, an oral treatment candidate for Kennedy’s Disease, also known as spinal and bulbar muscular atrophy (SBMA).

The study, presented by Dr. Tahseen Mozaffar, leader of a participating trial site, showed positive functional outcomes and strong therapeutic potential. The presentation given by Dr. Mozaffar was chosen as one of only seven Late-Breaking Abstracts, a special recognition reserved for research with important new findings.

AJ201 offers hope as the first potential disease-modifying therapy for Kennedy’s Disease in over two decades.

Read the news release on AnnJi’s website: https://www.ajpharm.com/news/index/2/184

Read the press release on PR Newswire: https://www.prnewswire.com/news-releases/annji-showcases-clinical-breakthrough-of-aj201-at-wms-2025-302581832.html